NEW YORK (GenomeWeb News) – Genomic test development firm GenomeDx today announced an expanded research agreement with the Mayo Clinic to include the exclusive licensing of certain Mayo IP.
The expanded deal also includes exclusivity covering co-developed IP, GenomeDx said, as well as continued access to clinical data around Mayo's cohort of prostate cancer samples, allowing the company longer-term follow up and the evaluation of biomarkers. It and Mayo initially collaborated in 2009, which resulted in the development of Decipher, a predictive test for men with prostate cancer for the risk of metastasis.
"Access to the Mayo Clinic's comprehensive cohort of samples from patients classified as high risk for metastatic disease and the involvement of Mayo Clinic researchers has been essential to the development of Decipher," GenomeDx CEO Doug Dolginow said in a statement. "With Mayo Clinic's large collection of patient samples that had developed metastatic disease, we could reliably identify and validate gene sequences associated with lethal prostate cancer and create the Decipher test."
Financial and other terms of the expanded deal were not disclosed.